Cloud-Clone touts small-molecule ELISA kits for neuroimmune research

Cloud-Clone Corp. is promoting its hapten-based competitive ELISA kits for measuring small-molecule messengers such as melatonin, cortisol, serotonin and histamine. The company says the kits are designed to improve sensitivity, specificity and workflow speed for research labs working on sleep, stress, immunity and metabolism.

Why it matters: - Small molecules such as melatonin, cortisol, serotonin and histamine help regulate sleep, stress, mood, immunity and inflammation. - Better measurement tools can support research on neuroendocrine, immune and metabolic disorders. - Cloud-Clone is positioning its kits for labs that need quantitative data from serum, urine and other biological samples.

What happened: - Cloud-Clone Corp. introduced its Small Molecule ELISA Kits as a hapten-based competitive assay platform for quantifying low-molecular-weight messengers. - The company says the kits are aimed at small molecules that cannot be measured with a classic sandwich ELISA because they are not immunogenic. - The kits are designed for research use across neural regulation and immune-response targets.

The details: - Cloud-Clone says the kits deliver pg/mL or ng/mL sensitivity for trace-level detection. - The assays use custom antibodies with low cross-reactivity against isomers, analogs and metabolic derivatives. - Supported sample types include serum, plasma, tissue homogenate, cell lysate and cell culture supernatant. - The kits are validated for human, mouse, rat, rabbit, swine, horse, bovine, ovine and other species. - Cloud-Clone lists intra-assay CV below 10% and inter-assay CV below 12%. - The workflow uses standard microplate readers and completes full-plate detection in about 2 hours. - The company says the assays require minimal sample pre-processing and cost less per sample than mass spectrometry or chromatographic methods. - Cloud-Clone says each kit undergoes hapten design, sensitivity testing, stability testing and cross-reactivity validation before launch. - Reference publication counts cited by the company include melatonin at 86, corticosterone at 78, cortisol at 46, serotonin at 42 and histamine at 34.

Between the lines: - The pitch is less about a single product launch and more about Cloud-Clone’s effort to frame its portfolio as a lower-cost alternative to more complex analytical platforms. - The company is also using publication counts and cross-species validation to signal research credibility and market traction. - The focus on stress, sleep and immune markers suggests demand from labs studying connected biological pathways rather than isolated targets.

What's next: - Cloud-Clone says it will keep refining product performance and expand the number of detectable analytes. - The company is also aiming to support drug metabolism profiling, oncology research and pharmaceutical development. - The press release directs readers to the company’s social profiles on LinkedIn, Instagram, TikTok and X.

The bottom line: - Cloud-Clone is betting that faster, cheaper and more specific small-molecule ELISA kits will keep gaining ground in life science research.